A Phase I, Multicenter, Open-label Dose Escalation and Expansion Study of HKT288, Administered Intravenously in Adult Patients With Advanced Solid Tumors, Including Epithelial Ovarian Cancer and Renal Cell Carcinoma
Phase of Trial: Phase I
Latest Information Update: 18 Sep 2017
At a glance
- Drugs HKT 288 (Primary)
- Indications Carcinoma; Ovarian cancer; Renal cell carcinoma; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Novartis Pharmaceuticals
- 13 Sep 2017 Planned End Date changed from 30 Aug 2019 to 31 Aug 2019.
- 29 Aug 2017 Status changed from recruiting to suspended.
- 17 Feb 2017 According to ImmunoGen media release, Novartis dosing the first patient in a Phase 1 clinical trial in ovarian cancer and renal cell carcinoma (Dec 2016)